TR200200683T2 - Oral kontrollü salıverme formülasyonları. - Google Patents

Oral kontrollü salıverme formülasyonları.

Info

Publication number
TR200200683T2
TR200200683T2 TR2002/00683T TR200200683T TR200200683T2 TR 200200683 T2 TR200200683 T2 TR 200200683T2 TR 2002/00683 T TR2002/00683 T TR 2002/00683T TR 200200683 T TR200200683 T TR 200200683T TR 200200683 T2 TR200200683 T2 TR 200200683T2
Authority
TR
Turkey
Prior art keywords
controlled release
release formulations
oral controlled
oral
rivastigmine
Prior art date
Application number
TR2002/00683T
Other languages
English (en)
Inventor
Shah Rajen
Chandra Khanna Stish
Kalb Oskar
Ogorka Jorg
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200200683(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR200200683T2 publication Critical patent/TR200200683T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Örnegin, bir zaman kontrollü usulde rivastigmin gibi bir aktif ajanin terapötik olarak etkili dozunu salivermeye muktedir farmasötik kompozisyon.
TR2002/00683T 1999-09-29 2000-09-27 Oral kontrollü salıverme formülasyonları. TR200200683T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9923045.0A GB9923045D0 (en) 1999-09-29 1999-09-29 New oral formulations

Publications (1)

Publication Number Publication Date
TR200200683T2 true TR200200683T2 (tr) 2002-07-22

Family

ID=10861819

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00683T TR200200683T2 (tr) 1999-09-29 2000-09-27 Oral kontrollü salıverme formülasyonları.

Country Status (31)

Country Link
US (2) US20060246101A1 (tr)
EP (1) EP1216032B1 (tr)
JP (1) JP2003510268A (tr)
KR (2) KR20050100710A (tr)
CN (1) CN1213737C (tr)
AR (1) AR025792A1 (tr)
AT (1) ATE384517T1 (tr)
AU (1) AU769646B2 (tr)
BR (1) BR0014440A (tr)
CA (1) CA2379595A1 (tr)
CO (1) CO5210867A1 (tr)
CY (1) CY1107923T1 (tr)
CZ (1) CZ301455B6 (tr)
DE (1) DE60037897T2 (tr)
DK (1) DK1216032T3 (tr)
EC (1) ECSP003685A (tr)
ES (1) ES2299438T3 (tr)
GB (1) GB9923045D0 (tr)
HU (1) HUP0202744A3 (tr)
IL (2) IL148908A0 (tr)
MY (1) MY128759A (tr)
NO (1) NO331480B1 (tr)
NZ (1) NZ517335A (tr)
PE (1) PE20010568A1 (tr)
PL (1) PL200822B1 (tr)
PT (1) PT1216032E (tr)
RU (1) RU2281758C2 (tr)
SK (1) SK286651B6 (tr)
TR (1) TR200200683T2 (tr)
WO (1) WO2001022944A1 (tr)
ZA (1) ZA200202369B (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
NZ553587A (en) 2004-08-13 2010-12-24 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmacutically acceptable salt thereof
EA201001086A1 (ru) * 2004-08-13 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
CN103619514B (zh) 2010-09-20 2016-09-28 Spi制药公司 微包囊方法和制品
KR101990951B1 (ko) 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
CN106000294B (zh) * 2016-07-04 2019-04-30 三峡大学 一种高膨胀低收缩率膨润土及制备方法
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US4984807A (en) * 1990-01-12 1991-01-15 Baruch Shiryon Board game
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
DE69107461T2 (de) * 1990-08-07 1995-06-22 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
IL128043A (en) * 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
HUP0002296A3 (en) * 1997-07-01 2001-11-28 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
CN1406126A (zh) * 1998-10-01 2003-03-26 诺瓦提斯公司 新型缓释口服制剂
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system

Also Published As

Publication number Publication date
US20060246101A1 (en) 2006-11-02
ECSP003685A (es) 2002-05-23
KR20050100710A (ko) 2005-10-19
WO2001022944A1 (en) 2001-04-05
CA2379595A1 (en) 2001-04-05
NO20021452D0 (no) 2002-03-22
NO20021452L (no) 2002-03-22
KR20020038778A (ko) 2002-05-23
CZ301455B6 (cs) 2010-03-10
PL354075A1 (en) 2003-12-15
IL148908A (en) 2010-06-16
KR100661441B1 (ko) 2006-12-27
HUP0202744A2 (hu) 2003-01-28
SK286651B6 (sk) 2009-03-05
IL148908A0 (en) 2002-09-12
CY1107923T1 (el) 2013-09-04
GB9923045D0 (en) 1999-12-01
ES2299438T3 (es) 2008-06-01
DE60037897T2 (de) 2008-12-24
ZA200202369B (en) 2002-12-24
ATE384517T1 (de) 2008-02-15
AR025792A1 (es) 2002-12-11
US20110038897A1 (en) 2011-02-17
WO2001022944A8 (en) 2001-07-26
NO331480B1 (no) 2012-01-16
PT1216032E (pt) 2008-04-29
BR0014440A (pt) 2002-06-18
PE20010568A1 (es) 2001-05-29
CZ20021028A3 (cs) 2002-06-12
NZ517335A (en) 2003-10-31
EP1216032A1 (en) 2002-06-26
EP1216032B1 (en) 2008-01-23
MY128759A (en) 2007-02-28
CN1213737C (zh) 2005-08-10
SK4132002A3 (en) 2002-10-08
HUP0202744A3 (en) 2004-05-28
RU2281758C2 (ru) 2006-08-20
CO5210867A1 (es) 2002-10-30
AU769646B2 (en) 2004-01-29
PL200822B1 (pl) 2009-02-27
DE60037897D1 (de) 2008-03-13
JP2003510268A (ja) 2003-03-18
CN1376058A (zh) 2002-10-23
AU1019701A (en) 2001-04-30
DK1216032T3 (da) 2008-06-02

Similar Documents

Publication Publication Date Title
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
AP1954A (en) Controlled release compositions comprising nimesulide.
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
DZ3227A1 (fr) Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
ES2159591T3 (es) Composicion de liberacion controlada.
BR9810495A (pt) Composição farmacêutica
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
BR9607862A (pt) Composição farmacêutica filmogênica para administração transdérmica
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
IT1302682B1 (it) Composizioni farmaceutiche orali contenenti buprenorfina
AP2003002763A0 (en) Controlled release formulations for oral administration
ES2150404T1 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
MY128759A (en) Oral controlled release formulations
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
AU5063700A (en) S-nitroso- and s-nitro-n-acyl-l-cysteine-ester-derivatives as pharmacological substances and medicaments containing said compounds
IL122719A0 (en) Controlled release pharmaceutical compositions for oral administration containing nifedipine as active substance
MY145885A (en) Controlled release formulations for oral administration